1. Home
  2. STKE vs EQ Comparison

STKE vs EQ Comparison

Compare STKE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

N/A

Current Price

$2.20

Market Cap

61.4M

Sector

N/A

ML Signal

N/A

EQ

Equillium Inc.

HOLD

Current Price

$1.16

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
EQ
Founded
2002
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.4M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
STKE
EQ
Price
$2.20
$1.16
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
320.0K
1.0M
Earning Date
01-06-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,456,249.00
$4,392,000.00
Revenue This Year
$45.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.18
N/A
52 Week Low
$1.50
$0.27
52 Week High
$34.32
$2.35

Technical Indicators

Market Signals
Indicator
STKE
EQ
Relative Strength Index (RSI) N/A 46.86
Support Level N/A $1.05
Resistance Level N/A $1.22
Average True Range (ATR) 0.00 0.15
MACD 0.00 -0.04
Stochastic Oscillator 0.00 17.63

Price Performance

Historical Comparison
STKE
EQ

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: